Overview

SK-1401 (rhGM-CSF Agent for Inhalation) GM-CSF Inhalation Pharmacokinetic Study

Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
Objective: Evaluate Pharmacokinetics and determine the safety of GM-CSF single dose inhalation. Study Design: Pharmacokinetic open study
Phase:
Phase 1
Details
Lead Sponsor:
Niigata University Medical & Dental Hospital
Treatments:
Sargramostim